TIDES USA brings together scientists and industry leaders advancing peptide, oligonucleotide, mRNA, and genome editing therapeutics from discovery through manufacturing and commercialization. The conference focuses on the chemistry, manufacturing, analytical development, and delivery technologies required to bring these complex modalities to market.
Adesis supports biotech and pharmaceutical teams developing peptide therapeutics, antibody-drug conjugates (ADCs), and complex small molecules. From early discovery through process development and scale-up, our chemists help programs move efficiently from concept to clinic. We attend TIDES to connect with teams working on next-generation peptide and conjugate programs and to discuss how we can support their development and manufacturing challenges.
Learn more about the event at https://informaconnect.com/tides/.
Our team will be in Boston throughout TIDES to meet with biotech and pharmaceutical teams working on peptide therapeutics, ADCs, and complex small molecule programs.
Adesis is a U.S.-based contract development and manufacturing organization (CDMO) focused on complex chemistry. We partner with pharmaceutical, biotechnology, and advanced materials companies to advance programs from early discovery through specialty manufacturing with precision, speed, and reliability.
With more than 100,000 square feet of laboratory and manufacturing space across two Delaware sites, supported by additional manufacturing capacity in Ireland, and a scientific team comprised of approximately 80% PhD-level chemists. Adesis operates as a seamless extension of client R&D organizations – bringing deep technical expertise, rigorous quality systems, and practical execution to every program.
